Someone is methodically holding the price down, for whatever reason. The more I study these results and compare to a number of other NASH trials, the more it is disgustingly obvious that the company should have a market cap of at least $250-350 million right now, which is about 7.5x the current price, with a target market cap of $500M-700M.
All I can say is, get ready. An Allergan-like Tobira buy of Immuron is on the way from one of the Big Pharmas is coming at a massive, massive markup akin to the 1,800% mark-up Allergan paid for Tobira.
The exceptional safety profile unmatched by any other NASH drug solidifies the target price.
Add to My Watchlist
What is My Watchlist?
